PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Poly adenosine diphosphate-ribose polymerase inhibitors (PARPi) represent an effective therapeutic strategy for cancer patients harboring germline and somatic aberrations in DNA damage repair (DDR) genes. <i>BRCA1/2</i> mutations occur at 1–7% across biliary tract cancers (BTCs), but a broader spect...
Salvato in:
| Autori principali: | , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2020-08-01
|
| Serie: | Medicines |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/2305-6320/7/9/54 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|